Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lamivudine

FDA-approved product (tablet, oral), marketed as Epivir, Epivir-Hbv, Lamivudine.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Lamivudine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis B virus infection
  • Hepatitis
  • Hepatitis B virus infection
  • HIV infection
  • HIV-1 infection
  • Immunodeficiency disease
  • Infection
  • Inflammation
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
FDA pharmacologic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF05; FDA class Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Lamivudine, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA20.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli9.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis30.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lamivudine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lamivudine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus (HBV)

    NCT00140725 · start 2000-04

    Registered record
    Registry ID
    NCT00140725
    Conditions
    Chronic Hepatitis B
    Interventions
    Lamivudine plus Polyethylene glyco-interferon alfa-2b; Lamivudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2000-04
    Completion
    Not recorded
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B
    InterventionLamivudine plus Polyethylene glyco-interferon alfa-2b; Lamivudine
    PhasePhase 3
    Registry statusCompleted

  • A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection

    NCT00002183

    Registered record
    Registry ID
    NCT00002183
    Conditions
    HIV Infections
    Interventions
    Abacavir sulfate; Amprenavir; Lamivudine; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAbacavir sulfate; Amprenavir; Lamivudine; Zidovudine
    PhasePhase 1
    Registry statusCompleted

  • A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs

    NCT00002217

    Registered record
    Registry ID
    NCT00002217
    Conditions
    HIV Infections
    Interventions
    Lamivudine/Zidovudine; Abacavir sulfate; Amprenavir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionLamivudine/Zidovudine; Abacavir sulfate; Amprenavir
    PhaseNot applicable
    Registry statusCompleted

  • Changing to Nonprotease Inhibitor Treatment to Improve Side Effects

    NCT00021463

    Registered record
    Registry ID
    NCT00021463
    Conditions
    HIV Infections; Lipodystrophy
    Interventions
    Abacavir sulfate, Lamivudine and Zidovudine; Abacavir sulfate; Efavirenz; Nevirapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    342

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Lipodystrophy
    InterventionAbacavir sulfate, Lamivudine and Zidovudine; Abacavir sulfate; Efavirenz; Nevirapine
    PhasePhase 2
    Registry statusCompleted

  • An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B

    NCT00124241

    Registered record
    Registry ID
    NCT00124241
    Conditions
    Hepatitis B
    Interventions
    telbivudine; lamivudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2005-11
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B
    Interventiontelbivudine; lamivudine
    PhasePhase 2
    Registry statusCompleted